Viewing Study NCT07075250


Ignite Creation Date: 2025-12-24 @ 5:05 PM
Ignite Modification Date: 2025-12-27 @ 3:57 PM
Study NCT ID: NCT07075250
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-07-20
First Post: 2025-06-25
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platinum-Resistant Ovarian Cancer: A Prospective, Multicenter Clinical Study
Sponsor: Peking University People's Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module